ARCUTIS BIOTHERAPEUTIC
11.51
26-11月-24 16:45:00
15 分の遅延
株式
+0.74
+6.87%
本日の幅
10.57 - 11.64
ISIN
N/A
ソース
NASDAQ
-
Arcutis’ ZORYVE® (roflumilast) Awarded Best Eczema Treatment by Glamour
13 11 2024 08:00:00 提供 Nasdaq GlobeNewswire
-
Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update
06 11 2024 16:00:00 提供 Nasdaq GlobeNewswire
-
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 11 2024 16:00:00 提供 Nasdaq GlobeNewswire
-
23 10 2024 16:00:00 提供 Nasdaq GlobeNewswire
-
18 10 2024 08:20:14 提供 Nasdaq GlobeNewswire
-
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 10 2024 16:00:00 提供 Nasdaq GlobeNewswire
-
25 9 2024 01:00:00 提供 Nasdaq GlobeNewswire
-
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 9 2024 16:00:00 提供 Nasdaq GlobeNewswire
-
Arcutis Completes Enrollment of Phase 1b Alopecia Areata Study Evaluating ARQ-255
05 9 2024 08:00:00 提供 Nasdaq GlobeNewswire
-
Arcutis to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
22 8 2024 08:00:00 提供 Nasdaq GlobeNewswire
-
CORRECTION – Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update
14 8 2024 21:00:03 提供 Nasdaq GlobeNewswire
-
Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update
14 8 2024 16:00:00 提供 Nasdaq GlobeNewswire
-
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 8 2024 16:00:00 提供 Nasdaq GlobeNewswire
-
Arcutis to Report Second Quarter 2024 Financial Results and Host Conference Call on August 14, 2024
01 8 2024 16:00:00 提供 Nasdaq GlobeNewswire
-
Arcutis Announces ZORYVE® U.S. Co-promote Agreement with Kowa Pharmaceuticals America, Inc.
29 7 2024 07:35:00 提供 Nasdaq GlobeNewswire
-
Arcutis Launches ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis
29 7 2024 07:30:00 提供 Nasdaq GlobeNewswire
- <<
- <
- 1
- >